Saturday 17 October 2026
Export CMMB’s income statement to Excel — free account
Chemomab Therapeutics Ltd. Sponsored ADR
CMMB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 25.0% and free cash flow grew 47.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.27
0.02
−1.55%
Follow CMMB
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
4.42 | 2.37 | 9.00 | 23.66 | 23.66 | 6.18 | 6.18 | 4.32 | 4.98 | 9.08 |
Net Debt/EBITDA |
0.78 | 0.50 | 1.97 | 4.96 | 4.96 | 1.41 | 1.40 | 0.78 | 0.98 | 1.09 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.61 | 1.10 | 0.88 | 0.99 | 0.99 | 0.74 | 0.74 | 0.97 | 1.10 | 1.24 |
Capex/Depreciation |
(0.34) | 0.00 | (1.58) | 0.00 | 22.38 | 0.00 | (1.17) | (0.04) | 0.00 | (0.04) |
Interest Coverage |
(5.42) | (1,096.30) | 284.38 | — | (111.41) | (161.67) | — | — | — | — |
| (219.50%) | 0.00% | (46.29%) | 0.00% | (34.53%) | 0.00% | (56.60%) | (91.02%) | (91.34%) | (69.54%) | |
| (166.83%) | 0.00% | (36.93%) | 0.00% | (32.48%) | 0.00% | (51.47%) | (74.28%) | (71.30%) | (58.45%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (2,534.22%) | 0.00% | 0.00% | 0.00% | 0.00% | (303.83%) |
Return on Tangible Assets |
(190.37%) | (327.75%) | (55.75%) | (20.56%) | (20.66%) | (77.39%) | (78.20%) | (148.03%) | (106.68%) | (74.20%) |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(153.84) | (6.85) | (3.09) | (1.19) | (4.48) | (1.78) | (7.18) | (8.04) | (3.43) | (1.75) |
Cash per Share |
163.34 | 2.91 | 6.84 | 5.90 | 23.58 | 3.51 | 14.05 | 6.76 | 3.20 | 1.63 |
Shareholders Equity per Share |
138.56 | 1.93 | 6.32 | 5.93 | 23.70 | 3.18 | 12.73 | 5.79 | 3.02 | 1.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
138.56 | 1.93 | 6.32 | 5.93 | 23.70 | 3.18 | 12.73 | 5.79 | 3.02 | 1.93 |
Free Cash Flow |
(16.55) | (12.71) | (5.28) | (12.38) | (11.61) | (20.29) | (20.44) | (23.61) | (15.39) | (11.13) |
Working Capital |
14.09 | 3.53 | 10.52 | 60.04 | 60.04 | 34.99 | 34.99 | 16.06 | 12.82 | 11.95 |
Capital Expenditures |
(0.09) | (0.03) | (0.04) | (0.24) | 0.76 | (0.07) | (0.07) | 0.00 | — | 0.00 |
Net Current Asset Value |
13.37 | 3.51 | 10.17 | 59.80 | 59.80 | 34.90 | 34.90 | 15.74 | 12.61 | 11.95 |
| Other line items | ||||||||||
Quick Ratio |
4.36 | 2.09 | 9.00 | 0.00 | 23.66 | 5.99 | 6.18 | 4.32 | 4.98 | 9.08 |
Depreciation/Fixed assets |
1.78 | 6.67 | 0.16 | 0.05 | 0.10 | 0.10 | 0.16 | 0.22 | 0.21 | 0.40 |
Cash ROIC |
(50.96%) | (141.73%) | (23.47%) | (10.10%) | (9.47%) | (26.63%) | (26.82%) | (64.07%) | (55.19%) | (49.04%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | — | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(152.96) | (6.85) | (3.07) | (1.19) | (4.77) | (1.78) | (7.16) | (8.04) | (3.43) | (1.75) |
Capex per Share |
(0.88) | 0.00 | (0.02) | 0.00 | 0.29 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.52 | — | 0.27 | 0.16 | 0.85 | 0.99 | 1.65 | 1.40 | 1.37 | 2.38 |
Average Payables |
0.64 | 0.78 | 0.48 | 0.71 | 0.71 | 1.51 | 1.51 | 1.10 | 0.57 | 0.56 |
Average Assets |
16.26 | 12.97 | 16.12 | 38.41 | 38.41 | 53.71 | 53.71 | 32.61 | 19.56 | 15.39 |
Average Common Equity |
12.36 | 9.24 | 12.86 | 36.13 | 36.13 | 48.84 | 48.84 | 26.61 | 15.27 | 12.94 |
Capex to Sales |
0.00 | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — | 0.00 |
Columns are period end dates